706 results about "Hyperuricemia" patented technology

An extract of mulberry twigs is dislcosed, which can be used to prepare the food or the medicine to cure hyperuricemia and gout diseases. The said extract is prepared from mulberry twigs through extracting in solvent (aqueous solution of alcohol, chloroform, acetone, etc) at 10-100 deg.C more than one time, mergint the liquid extracts, recovering solvent, regulating pH value to 7.5-9.5, centrifugal separation to obtain supernatant, regulating pH value to 4-6, deposition, water washing wand drying. Several other approaches for purifying it are also disclosed.

The invention relates to application of celery seed extract to preparation of medicine or health-care food for resisting to hyperuricemia and gout and further provides medicine or health-care food for treating hyperuricemia and gout. Celery seed extract serves as the active constituent, and an appropriate number of medical carriers or auxiliary constituents are added, so that a preparation is obtained. The medicine for health-care food is simple in preparation process, the celery seed extract can obviously lower serum uric acid of model mice suffering from hyperuricemia caused by oteracil potassium salt, lower the activity of xanthine oxidase to different degrees, achieve an obvious inhibition effect on arthritis of the mice, prevent and treat hyperuricemia or gout and be applied to preparation of the medicine or health-care food for resisting to hyperuricemia and gout.

The invention discloses special dietary seafood special for hyperuricemia patients. The seafood is characterized by being prepared by taking food-derived marine bioactive polysaccharides as main raw materials, adding algae powder and mixing the food-derived marine bioactive polysaccharides and the algae powder with the auxiliary materials including nutritional amino acids, oligosaccharides, vitamins and minerals. The seafood can be powdery or granular and is eaten after being dissolved in warm water. The seafood is easy to dissolve, has maximum biological absorbance and maximum bioavailability in human bodies, provides marine active factors and nutritional components for human bodies, supplements various vitamins and minerals essential to human bodies, is beneficial to improving the nutritional status of the hyperuricemia patients and can assist in reducing the uric acid level and controlling the hyperuricemia level, improving the immune of the human bodies and preventing gout throughsynergy of such factors as bioactive components in the food-derived marine bioactive polysaccharides, the algae powder, the nutritional amino acids and the like, thus being suitable for the hyperuricemia patients.

A compound represented by following general formula (I):

wherein, represents a single bond or a double bond; L represents —NH— or the like; X¹ represents N or C, provided that in the case where X¹ is N, X² represents C—R and in the case where X¹ is C, X² represents N—R¹ or the like; Y's may be either the same or different and represent CH₂ or the like; A represents a non-natural sugar residue represented by following general formula:

wherein, m represents 0 to 1; represents a single bond or a double bond; X represents O or the like; R³ to R⁸ may be either the same or different and represent hydroxy group or the like; and B represents a group represented by following general formula:

wherein, n and k represent 0 to 5; represents a single bond or a double bond; Z¹ to Z¹⁶ may be either the same or different and represent CH or the like; R¹⁰ and R¹¹ may be either the same or different and represent a lower alkoxy group having 1 to 5 carbon atoms or the like; and R¹⁵ represents a hydrogen atom or the like, a pharmaceutically acceptable salt thereof, a prodrug thereof, a hydrate thereof or solvate thereof. Because of having an excellent CNT2 inhibitory activity and showing a high in vivo stability and stable physicochemical properties, the aforesaid compound is useful as a remedy for hyperuricemia.

A composition composed of a Lactobacillus bacterium, Bifidobacterium longum, and xylooligosaccharide is provided for use in reducing uric acid levels in the blood and preventing or treating hyperuricemia or gout.

The invention disclosed an aryl nitrile group thiazole derivative for inhibiting the activity of xanthine oxidase, a method for preparing the same and application thereof. In the aryl nitrile group thiazole, R1 is methyl, ethyl, propyl, isopropyl, isobutyl, methyl cyclopropane, methyl cyclobutane, isoamyl, methyl cyclopentane, methyl cyclohexane or aromatic ring methyl, R2 is methyl or trifluoromethyl, and R3 is formic acid, sodium formate, potassium formate, lithium formate, methyl formate, or ethyl formate. Simultaneously, the invention discloses a method for synthesizing the aryl nitrile group thiazole derivative by using inexpensive raw materials, which has the advantages of simple operation, high yield, easy purification of products, application to industrial production and the like, and can obtain an efficient compound with low toxicity through screening; besides, the effective compound is expected to be widely applied to inhibit the activity of the xanthine oxidase required on animals and humans, and to become a new generation of antigout drugs and hyperuricemia drugs with special effect.

Provided is an enteric preparation for preventing and curing hyperuricemia and gout. The employing essential component of the preparation is enteric capsules of uricase. The causes of the hyperuricemia and the gout are that uric acid is over generated and / or the uric acid is diminished in discharging, and metabolic diseases increasing the density of serum uric acid. About one third of the uric acid of the human body is defecated from intestinal canals, and the uric acid entering the canals still can be reabsorbed. When the hyperuricemia and the gout happen, the proportion of the uric acid defecated from the intestinal canals is increased. The uricase is capable of rapidly effectively dissociating the uric acid. The uricase of the enteric preparation after being orally taken is disintegrated in the intestinal canals and is diffused from blood into the uric acid of the intestinal canals, preventing the uric acid from reabsorbing, thereby reducing the density of the serum uric acid, achieving the purposes of preventing and curing the hyperuricemia and the gout. The oral uricase has the characteristics of non-absorbent property by the intestinal canals, keeping out of blood circulation, no producing of antibodies of organisms and allergic response, providing a new method for preventing and curing the hyperuricemia and the gout.

The invention relates to a traditional Chinese pharmaceutical composition for treating gout and its preparing process, wherein the composition is prepared from sharpleaf galangal fruit, corktree bark, ash bark, polyporus umbellatus, oriental water plantain rhizome, plantain herb, coralbean bark, root of bidentate achyranthes, raw material and medicinal adjuvant. The composition can be prepared into various pharmaceutically acceptable oral preparations.

The invention belongs to the field of medicines and discloses a mango leaf extract and application thereof. Mango leaves are subjected to refluxing extraction and concentration via aliphatic alcohol with 1-4 carbon atoms, and the obtained product is extracted and purified via low-polarity organic solvent and is refined to obtain the mango leaf extract. The mango leaf extract disclosed by the invention contains mangiferin and homomangiferin which are at specific proportion, and is better than a mangiferin monomer in the solubility. Pharmacological research proves that the mango leaf extract has the effects of lowering the level of serum uric acid of a hyperuricemia mice and reducing blood sugar, and is better than the mangiferin. Therefore, the invention provides application of the mango leaf extract provided by the invention to the medicine for preventing or treating the metabolic syndrome.

The invention discloses an L.plantarum UA149 strain and an application thereof, and belongs to the field of functional food microorganisms. The L.plantarum UA149 strain is deposited in China Typical Culture Collection Center on November 29, 2018 with the preservation number of CCTCC No: M2018842. The strain can be apply to preparing products with a uric acid reducing function or a gout resisting function. Lactic acid bacteria separated and identified from the surface of fleshy plant leaves are taken as research objects, and a new strain of lactic acid bacteria is screened through a large number of experiments. Hyperuricemia model rats are established by potassium oxazinate combined with fructose water, continuous intragastric administration of the lactobacillus plantarum UA149 strain for 14 days can significantly reduce the level of uric acid; and during gout attack, the release of inflammatory factors thromboxane and leukotriene mediated by neutrophils is reduced, the influx of neutrophils into joints is avoided, and the symptoms of redness, swelling, pain, heat and the like are reduced.

The invention relates to an application of Graveobioside A in the preparation of drugs or healthcare food for preventing hyperuricemia and gout. The invention also provides a drug or healthcare food for treating hyperuricemia and gout. Graveobioside A is the active component and is mixed with a proper amount of pharmaceutical carrier or excipient to prepare preparations. Graveobioside A can prominently reduce uric acid in serum of an oteracil potassium caused hyperuricemia model mouse, reduces the activity of xanthine oxidase at different levels, and prominently inhibit the arthritis of mouse. Graveobioside A can treat and prevent hyperuricemia and gout and can be used to prepare drugs or healthcare food for preventing hyperuricemia and gout.

The invention relates to use of vegetable extract in inhibiting xanthine oxidase (XO) and application in preparing food for preventing and treating hyperuricemia or gout. The vegetable extract is prepared by the following steps: a methanol extraction process: removing impurities from fresh vegetable, and removing moisture in an electrothermal blowing drying box at 40 DEG C; crushing the vegetableinto powder by a crusher; weighing a certain amount of dry vegetable into a conical flask, and extracting by methanol ultrasonic wave twice for 45 minutes in each extraction; filtering to remove the filter residue; recycling the solvent from the filtrate by a rotary evaporator, and drying the remainder in an electrothermal vacuum drying box to obtain extractum; and applying the vegetable methanolextract to an in vitro XO inhibition test so as to screen out the vegetable crude extract with the effect on inhibiting the XO. The invention provides an reference on diet for preventing and treatinggout or hyperuricemia.

The present invention relates to 5-Aryltetrazole compounds, compositions comprising a 5-Aryltetrazole compound, and methods for treating an inflammation disease, a reperfusion disease, hyperuricemia, gout, or tumor-lysis syndrome in an animal in need thereof comprising administering to the animal an effective amount of a 5-Aryltetrazole compound.

The invention belongs to the technical field of medicines, relates to eurycoma longifolia Jack extract and eurycomanone and a preparation method thereof, and also relates to use of the eurycomanone and the eurycoma longifolia Jack extract and a composition containing the eurycomanone and the eurycoma longifolia Jack extract in preparing of anti-tumor, anti-gout and anti-hyperuricemia drugs, health food, functional food and food. The eurycoma longifolia Jack extract is obtained by taking a dry eurycoma longifolia Jack medicinal material, extracting with water or alcohol, concentrating liquid extract, recovering a solvent and drying. The eurycomanone is obtained by using a solvent for gradient elution of the eurycoma longifolia Jack extract by silica gel column chromatography. Refined high purity target compound eurycomanone can be obtained by recrystallization treatment when necessary (when the eurycomanone contains a small amount of impurities or pigments and the like).

The invention discloses application of cannabinoids in the preparation of a medicine for treating gout. The inventor found for the first time that cannabinoids have a very strong antigout effect, can significantly reduce serum urate level of hyperuricemia mice but have no remarkable influence on serum urate level of normal mice, can substantially inhibit toe swelling induced by sodium urate, have more excellent activity than allopurinol and have little toxic and side effect. The invention also provides a gout-treating medicinal preparation of the cannabinoids and a corresponding dosage form. By a conventional preparation method, various different dosage forms of medicines used in clinic can be prepared and are convenient to use.

The invention provides an effective part of chicory (or jerusalem artichoke) for preventing and curing hyperuricemia and a preparation thereof, wherein the effective part is prepared by the following method comprising the following steps of: extracting the chicory (or the jerusalem artichoke) with water for 1-5 times with 3-20 times of water at each time, wherein the extracting time at each time is 0.5-2.5 hours; and precipitating a chicory (or jerusalem artichoke) water extract with 40-percent ethanol, filtering and recovering the ethanol to obtain the 40-percent amylose effective part. The effective part has definite curative effect in the aspects of preventing and curing the hyperuricemia, can be used for preventing and curing the hyperuricemia, the hyperuricemia plus hypertriglyceridemia, the hyperuricemia plus hyperglycemia and the hyperuricemia plus blood hypercoagulation and blood hyperviscosity and has no obvious toxic or side effect or adverse reaction.

The invention provides sunflower head extract prepared by a crystallization enzymolysis method and a preparation method of the sunflower head extract. A sunflower head is a pure natural traditional Chinese medicine or a material both used as medicine and food; the sunflower head is scientifically extracted to prepare a functional health product both used as medicine and food, which has the effects of resisting gout, treating hyperuricemia, improving the immunity, lowering blood glucose and blood lipid, protecting kidney and liver, eliminating swelling, resisting inflammation and relieving pain and has the effects of dissolving uric acid calculus, lowering serum uric acid concentration, eliminating swelling and resisting inflammation, adjusting purine and uric acid metabolism, balancing in-vivo acid-base equilibrium and balancing in-vivo hormones; the product is safe, has no side effect, has remarkable health effect and can be eaten for a long period, so that a market development prospect is very good.

The present invention is directed to certain novel triazole compounds represented by Formula I and pharmaceutically acceptable salts, solvates, hydrates, and prodrugs thereof. The present invention is also directed to methods of making and using such compounds and pharmaceutical compositions containing such compounds to treat or control a number of diseases mediated by PPAR such as glucose metabolism, lipid metabolism and insulin secretion, specifically Type 2 diabetes, hyperinsulemia, hyperlipidemia, hyperuricemia, hypercholesteremia, atherosclerosis, one or more risk factors for cardiovascular disease, Syndrome X, hypertriglyceridemia, hyperglycemia, obesity, and eating disorders.

The present invention relates to methods for preventing the progression of joint damage in a subject having hyper-uricemia and who has gout thereof by administering a therapeutically effective amount of at least one xanthine oxidoreductase inhibiting compound or salt thereof. Moreover, the present invention also relates to methods of preventing joint damage in a subject having hyperuricemia and who has gout by administering a therapeutically effective amount of at least one xanthine oxidoreductase inhibiting compound or salt thereof.

The invention discloses a dendrobium officinale leaf extract with a uric acid reducing function and application of the dendrobium officinale leaf extract. The dendrobium officinale leaf extract is prepared through the following steps: cleaning and drying the dendrobium officinale leaves; mechanically pulverizing; carrying out reflux extraction by a 0-30V% ethanol solution for 1-3 times, wherein the time of each reflux extraction is 1-3h and the dosage of each reflux extraction is 5-20 times of the medicine weight; combining the filtrates; recovering the ethanol; and carrying out vacuum concentration to obtain the dendrobium officinale leaf extract. The dendrobium officinale leaf extract can be used for preventing medicines or food for preventing and treating hyperuricemia; the dendrobium officinale leaf extract relies on the dendrobium officinale leaves to develop the effects of the dendrobium officinale leaves, so that the new medicinal resources of the dendrobium officinale are expanded and the resource waste is decreased at the same time.